GnRH agonist + human chorionic gonadotropin

This combination treatment protocol is used for final oocyte maturation in patients with Polycystic Ovary Syndrome (PCOS) undergoing In Vitro Fertilization (IVF) or Intracytoplasmic Sperm Injection (ICSI). The protocol involves the administration of a Gonadotropin-Releasing Hormone (GnRH) agonist (such as triptorelin) to trigger an endogenous surge of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), followed by a low dose of human chorionic gonadotropin (hCG) (typically 1500 IU) administered shortly after egg retrieval to provide sustained luteal phase support. This "dual trigger" or "agonist trigger with hCG rescue" approach is specifically designed to minimize the risk of Ovarian Hyperstimulation Syndrome (OHSS), a potentially severe complication in high-responder patients, while maintaining optimal oocyte yield and clinical pregnancy rates. This specific intervention was evaluated in a Phase 4 clinical trial (NCT01833936) sponsored by the AZ Jan Palfijn Gent hospital in Belgium.

Other names

GnRH agonist + 1500E hCGGnRH agonist triggering + hCG rescueGnRH agonist + hCG-AZ Jan Palfijn Gent-infertility